Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alkaline Glucosodiene in Metastatic Breast Cancer
NCT05957939Phase 1Unknown
- Sponsor
- Ministry of Health
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of alkaline glucosodiene in breast cancer, sponsored by Ministry of Health. Primary endpoints: Progression-Free Survival at 30 days and Disease-Free Survival at 30 days. Status: unknown.
02
Drugs
alkaline glucosodiene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05957939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957939.